Future work, based on the availability of funding, will be required to perform in vivo studies in transgenic Tau and APP mice to define whether these drugs have therapeutic efficacy against Alzheimer’s Disease mouse models. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.